黑料不打烊

Europe Blood Glucose Monitoring Market Trends and Insights

Rising Diabetes Prevalence & Ageing Population

Europe counted 61 million adults living with diabetes in 2025, and the International Diabetes Federation projects this figure will reach 68 million by 2030. Germany documented 8.5 million diagnosed cases in 2025, a 9% rise from 2020, while Poland鈥檚 prevalence hit 7.2% amid rural diagnostic gaps ^{[1]International Diabetes Federation, 鈥淚DF Diabetes Atlas 2025,鈥� diabetesatlas.org}. People aged 65-plus, whose diabetes incidence is 3.2-times higher than the working-age group, are expanding fastest in Italy, Spain, and Portugal, prompting suppliers to design CGMs with larger displays and voice prompts to suit dexterity or cognitive limitations. These demographics underpin sustained unit demand for both sensors and test strips. Consequently, the Europe blood glucose monitoring market continues to see stable baseline volumes even as per-patient strip consumption falls.

CGM鈥揝MBG Accuracy Convergence & Hybrid Data Platforms

Peer-reviewed trials in The Lancet Diabetes & Endocrinology showed leading CGM systems achieving mean absolute relative difference (MARD) values below 9%, effectively matching laboratory standards and removing the calibration rationale for SMBG. Abbott FreeStyle Libre 3 and Dexcom G7 both secured ISO 15197:2013 certification without finger-stick validation, triggering Germany鈥檚 G-BA to reimburse CGM for basal-insulin Type-2 users from July 2025 ^{[2]G-BA Germany, 鈥淧ress Release July 2025,鈥� g-ba.de}. Hybrid data platforms now merge CGM feeds with insulin-pump algorithms and electronic health records, elevating closed-loop accuracy and squeezing the EUR 0.45 per-test price edge that SMBG once held. As decision makers weigh the total cost of care, strip-based economics alone can no longer shield SMBG from share erosion. 

Expanded Public Reimbursement for CGM Across EU-5

NHS England committed GBP 350 million annually in April 2024 to provide flash and real-time CGM to every insulin-treated patient. France鈥檚 Haute Autorit茅 de Sant茅 followed in September 2024, extending coverage to poorly controlled Type-2 patients on multiple daily injections. Italy and Spain enacted similar, though regionally nuanced, funding schemes in 2025 that tie payment to hypoglycemia reduction metrics. These actions collectively expand the reimbursable universe by more than 1.2 million European users within two years, giving CGM its strongest demand shock in a decade.

Digital-Health Integration Enabling Virtual Diabetes Clinics

Post-pandemic, 42% of diabetes follow-ups in the Nordics occurred virtually in 2025, up from 18% in 2020, thanks to cloud dashboards that let clinicians titrate insulin remotely. Stockholm鈥檚 CGM data hub shortened waiting lists by 30% and improved HbA1c by 0.4 percentage points. Danish pilots pairing CGM with AI coaching apps reached 78% engagement, showing that behavioral nudges can amplify sensor value. These gains embolden payors to shift routine care to home settings, amplifying sensor sales through direct-to-consumer channels.

High Cost of CGM Devices & Consumables

Out-of-pocket spending remains a hurdle where reimbursement is partial or absent. Italian users paid EUR 120-160 per month for Libre sensors in 2025, 12% of the median disposable income in the south ^{[3]Italian Diabetes Society, 鈥淎ccess Report 2025,鈥� siditalia.it}. Spain鈥檚 autonomous regions showed 70% coverage in Catalonia but only 18% in Extremadura, fuelling legal challenges from patient groups. Poland funds CGM solely for children, leaving 280,000 adult insulin users on SMBG strips that cost EUR 35 monthly, reinforcing health inequities.  

Semiconductor-Grade MEMS Supply-Chain Constraints

CGM sensors use electrochemical electrodes built on silicon wafers, competing for foundry slots also serving automotive chips. During the 2024-2025 shortage, Dexcom faced 38-week ASIC lead times and prepaid EUR 45 million in wafer inventory. Abbott dual-sourced platinum-iridium electrodes to buffer risk, stockpiling 60 days of safety inventory. Any renewed silicon crunch could again expose the market to short-term stock-outs.

Segment Analysis

By Device Type: CGM Gains as SMBG Defends Legacy Base

SMBG still accounted for 60.1% of Europe's blood glucose monitoring market share in 2025, buoyed by entrenched reimbursement for Type-2 patients on oral agents and the 12 million-unit installed base of finger-stick users. Roche Accu-Chek Guide and LifeScan OneTouch Verio Reflect anchor pharmacy contracts, though their test-strip volumes slipped 4-6% in 2025 as CGM accelerated among insulin users. The European blood glucose monitoring market size linked to CGM is forecast to expand at 10.23% CAGR, propelled by accuracy parity, ISO certification without calibration, and interoperability with closed-loop pumps. 

Emerging non-invasive wearables鈥擝iolinq鈥檚 microneedle patch and Nemaura鈥檚 sugarBEAT鈥攅ntered limited pilots in 2025, courting the 8 million pre-diabetics who refuse finger pricks. Medtronic鈥檚 Guardian 4 sensor reached 18% of new CGM starts in Germany within six months of its March 2025 launch, underscoring the momentum behind fully integrated systems. To blunt share loss, SMBG vendors now bundle Bluetooth meters with analytics portals, seeking to shift dialogue from 鈥渄evice鈥� to 鈥渄ata鈥� even as per-test economics erode.

Note: Segment shares of all individual segments available upon report purchase

By Diabetes Type: Type-1 Intensity Meets Type-2 Volume

Type-2 cases delivered 73.21% of revenue in 2025, confirming their numeric dominance, yet Type-1 drives disproportionate growth and technology mix. The Europe blood glucose monitoring market size earned from Type-1 users is projected to climb 13.5% CAGR, as pediatric guidelines prescribe CGM as standard of care and closed-loop systems proliferate. Germany leads with 78% CGM penetration among Type-1 patients. 

Type-1 patients also spend 4.2-times more per capita on sensors and pump supplies than Type-2 SMBG users, concentrating manufacturer margins. Expanded reimbursement for Type-2 CGM now hinges on clinical demonstration of hypoglycemia reduction rather than glycemic averages alone, a hurdle that vendors are actively studying. Broader inclusion of pre-diabetes monitoring could unlock 18 million additional users, but supportive cost-effectiveness dossiers remain a prerequisite. 

By Age Group: Pediatrics Surge, Geriatrics Lag

Adults represented 73.1% of 2025 revenue, yet pediatrics outpaces every cohort with a forecast 14.31% CAGR. Sweden鈥檚 school-based program put CGM in 92% of Type-1 children by 2025, cutting emergency admissions by 44%. 

Geriatric uptake sits at 19% despite accounting for 28% of diabetic Europeans, constrained by manual dexterity hurdles and skepticism toward new tech. Abbott鈥檚 caregiver-view feature lifted German and Dutch senior adoption 18% year-on-year. Italy鈥檚 pilot that couples CGM with weekly tele-consults achieved 72% adherence, signalling that wrap-around services, rather than hardware alone, can unlock this conservative segment. 

Note: Segment shares of all individual segments available upon report purchase

By Test Type: Invasive Dominance Faces Non-Invasive Challenge

Invasive modalities, spanning SMBG and minimally invasive CGM, held 59.12% share in 2025, supported by pump integration requirements. Non-invasive technologies are projected to grow at 10.78% CAGR through 2031 as patients gravitate toward pain-free options. Nemaura鈥檚 sugarBEAT registered 12.3% MARD in trials, good enough for private-pay segments, though still shy of public-funding thresholds.

Biolinq鈥檚 intradermal patch, now in CE-mark review, positions itself as 鈥渧irtually non-invasive,鈥� offering 14-day wear with no skin breach and targeting launch in 2026. For pump-dependent users, however, invasive CGM retains an accuracy and real-time advantage, especially for automated insulin delivery algorithms that adjust every five minutes. As such, invasive systems will dominate high-acuity segments even while non-invasive gains share among lifestyle-managed Type-2 and pre-diabetic populations. 

By End User: Homecare Ascends, Hospitals Retreat

Homecare settings delivered 41.34% of revenue in 2025 and are projected to climb 9.87% CAGR, reflecting enduring patient preference for remote monitoring. German sickness funds reported 68% of endocrinology consults were virtual by 2025, trimming per-patient costs by EUR 340.

Hospitals accounted for a significant share but face slower growth as reimbursement rarely covers inpatient sensor use. Abbott鈥檚 Libre Pro addresses staff workload with retrospective reporting, but adoption remains low. Direct-to-consumer e-commerce, classified under 鈥淥thers,鈥� surged significantly in 2025 after Dexcom and Abbott launched subscription delivery, underscoring a retail-health tilt that reshapes channel strategy.

Geography Analysis

Germany commanded 26.76% of the Europe blood glucose monitoring market share in 2025, backed by statutory coverage that funds CGM for all Type-1 and select high-risk Type-2 patients. CGM penetration among German insulin users reached 78%, and sickness funds have started outcome-based contracts that further reward sensor adherence.

The United Kingdom is the fastest-growing territory with an 11.23% CAGR forecast to 2031, thanks to NHS England鈥檚 GBP 350 million program that extends flash and real-time CGM to 400,000 insulin-treated individuals. Suppliers set up direct distribution to support home delivery, bypassing pharmacy margin drag and enabling swift scale-up. France follows, with HAS expanding reimbursement to Type-2 multiple-daily-injection patients, though roll-out speed is uneven across rural d茅partements.

Spain and Italy exhibit regionally fragmented access. Catalonia hit major CGM coverage. Italy鈥檚 pay-for-performance scheme links reimbursement to hypoglycemia reduction, shifting risk to vendors yet catalyzing adoption among cash-strapped health authorities. The Netherlands reaches 64% Type-1 penetration under a time-in-range payment model. Nordic nations collectively hold notable market share, but punch above their weight in virtual-clinic innovation and pediatric adoption. Eastern Europe remains SMBG-centric due to budget constraints, although Poland has signalled adult CGM funding from 2027.